The Canadian-based biotech company, Mountain Valley MD is changing the accessibility of vaccines to people around the world. With the mission of “more life, less death” the company is striving to make vaccines widely available to developing nations/ economies and people around the world.
- Vaccine soluble tablet that rapidly dissolves
- Does not have to be stored at dramatic high or cold temperatures
- Can be distributed easily around the world
- Helps more people in need and saves lives, due to access to high-quality vaccines
- Working towards the goal of eradicating diseases such a Polio, COVID-19 and other highly infectious diseases or viruses
Dennis Hancock is a senior sales and marketing executive with over 25 years of experience spanning automotive, pharmaceutical, tech, telco, retail and financial services sectors. Initially providing consulting services to Mountain Valley MD in 2018, Dennis transitioned to assume the President & CEO position in early 2019 to lead the Company’s go-public strategy and develop the business strategy to pursue broad health and wellness opportunities across human, animal and plant health applications. Dennis spent more than 12 years in a leadership role at one of North America’s leading performance improvement and Loyalty providers, Maritz, who works with 70% of the world’s Super 50 companies. Previously, Dennis led publicly-traded ZENN Motor Company as the Vice President of Sales and Marketing. As a senior officer at ZMC, Dennis drove the establishment of ZENN – (Zero Emission, No Noise) as one of the most recognized “green tech” brands in North America. Dennis has several start-ups established, including PerformanceSPARK, an agency that works with leading organizations to identify and deliver on the key elements necessary to drive measurable performance growth, and co-founder of CrowdSeating Inc., an innovative social concert platform.
Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome™️️️ oral drug formulation and delivery technologies and its Quicksol™️️️ solubilization technology for macrocyclic lactones, to innovate industry-leading products that are sought out globally. MVMD’s proposition for delivering Quicksome™️️️ formulations that have a rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™️️️ and Quicksol™️️️ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. The Company’s patented Quicksome™️️️ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Company’s patented Quicksol™️️️ solubilization technology covers all highly solubilized macrocyclic lactones (including the drugs Ivermectin and Selamectin). MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that only uses excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.
This podcast is brought to you by Schneider Electric. Supporting Canadian businesses with innovative energy management and automation solutions. Schneider Electric…your digital partner for Sustainability and Efficiency. Click here to learn more.
Want to stay up-to-date on the latest #entrepreneur podcasts and news? Subscribe to our bi-weekly newsletter